CYPHERPUNK TECHNOLOGIES INC. (CYPH): Nasdaq/NYSE listing notice — Leap Therapeutics receives Nasdaq bid price deficiency letter; has until May 1, 2023 to regain compliance

CYPHERPUNK TECHNOLOGIES INC.

Closing bid price below $1.00 for 30 consecutive business days triggered Nasdaq deficiency notice.
Company has 180 days (until May 1, 2023) to regain compliance by closing at $1.00 for 10 consecutive days.
If not compliant by May 1, may be eligible for an additional 180-day period subject to other listing standards.
Failure to cure could result in delisting; company may appeal to Nasdaq Hearings Panel.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

CYPHERPUNK TECHNOLOGIES INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

November 2, 2022, Leap Therapeutics, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common stock was below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The notification received has no immediate effect on the Company’s Nasdaq listing. In accordance with Nas

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

CYPHERPUNK TECHNOLOGIES INC. filing history →

Source: SEC EDGAR

accession 0001104659-22-114996

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.